Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774590 | 0.88 | GAA (0.52) | SRD5A2NPC1RAB9A | |
| SCHEMBL1773728 | 0.84 | CES2 (0.53) | SRD5A2CES2KITRAB9A | |
| SCHEMBL1773658 | 0.81 | MAPT (0.47) | SRD5A2CES2CES1RAB9A | |
| SCHEMBL11101475 | 0.80 | PTGS2 (0.51) | CES2CES1CYP2C8NPC1RAB9A | |
| SCHEMBL25850063 | 0.79 | TAS2R14 (0.52) | SRD5A2CES2NPC1RAB9A | |
| SCHEMBL14415777 | 0.79 | CES2 (0.50) | CES2CES1NPC1RAB9A | |
| SCHEMBL9776286 | 0.79 | SRD5A2 (0.53) | SRD5A2BCL2L1CES2CES1CYP2C8 | |
| SCHEMBL1773115 | 0.78 | KMT2A (0.50) | NPC1RAB9A | |
| SCHEMBL1773507 | 0.78 | CDC25B (0.51) | BCL2L1NPC1RAB9A | |
| SCHEMBL1773321 | 0.78 | GSK3B (0.47) | SRD5A2CYP1A1CYP1B1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| EP-2242747-A1 | SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009097997-A1 | SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | SRD5A2 166/4885BCL2L1 3943/4885CYP1A1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.